Arrowhead Pharmaceuticals, Inc.
ARWR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000879407
In the last 90 days, Arrowhead Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 2 sales; 503 institutions reported holding it in 13F filings for Q2 2026, worth $9.75B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 9, 2026
- $6.96B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.19M in total
- 2
- 13F holdersQ2 2026, +71 vs. previous quarter
- 503
- 13F valueReported value at the end of Q2 2026
- $9.75B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $829.4M
- +23,258.2% year over year
- Net income, FY2025
- -$1.63M
- No comparable prior period
- Free cash flow, FY2025
- $156.9M
- No comparable prior period
- Revenue, Q3 FY2026
- $75.3M
- +171.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $1.63M (0.2% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 11.0M
- Shares sold short
- Change
- +198.8K
- +1.9% vs. previous
- Days to cover
- 5.36
- At average daily volume
Superinvestors holding ARWR, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ARWR at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Arrowhead Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 20, 2026 (view filing)5:25 PM ET | Aug 18 | 2 days | Olukotun Adeoye YDirector | SSale | −2.00K | $86.96 | −$173.9K | −6.0%31.6K after | |
| Aug 20, 2026 (view filing)5:22 PM ET | Aug 18 | 2 days | Perry Michael SDirector | SSale | −11.6K | $87.30 | −$1.01M | −9.4%111.5K after | |
| May 14, 2026 (view filing) | May 12 | 2 days | Lu HongboDirector | SSale | −2.97K | $76.88 | −$228.3K | −5.4%52.0K after | 10b5-1 |
| Apr 24, 2026 (view filing) | Apr 23 | 1 day | Hamilton James CChief Medical Officer | SSale | −10.0K | $75.00 | −$750.0K | −4.2%227.0K after | 10b5-1 |
| Apr 24, 2026 (view filing) | Apr 22 | 2 days | Apel Daniel JosephChief Financial Officer | SSale | −13.1K | $71.35 | −$934.3K | −7.4%162.9K after | 3 lots10b5-1 |
| Mar 9, 2026 (view filing) | Mar 5 | 4 days | Hamilton James CChief Medical Officer | SSale | −10.0K | $64.19 | −$641.9K | −4.0%237.0K after | 10b5-1 |
| Jan 5, 2026 (view filing) | Jan 5 | Same day | Hamilton James CChief Medical Officer | SSale | −40.2K | $63.11 | −$2.53M | −18.9%172.0K after | 7 lots10b5-1 |
| Jan 5, 2026 (view filing) | Jan 5 | Same day | O'Brien PatrickCOO | SSale | −49.5K | $63.11 | −$3.12M | −9.4%474.9K after | 12 lots10b5-1 |
| Jan 5, 2026 (view filing) | Jan 2 | 3 days | Anzalone Christopher RichardChief Executive Officer | SSale | −13.2K | $66.10 | −$871.7K | −0.3%3.79M after | 2 lots10b5-1 |
| Dec 30, 2025 (view filing) | Dec 26 | 4 days | Ferrari MauroDirector | SSale | −7.53K | $70.00 | −$527.1K | −9.8%69.1K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 503 holdersThe largest institutional positions in Arrowhead Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 14,830,553 | $1.21B | 0.02% | −3,330,966−18.3% | Reduced |
| Avoro Capital Advisors LLC | 11,355,555 | $925.6M | 8.31% | +655,556+6.1% | Added |
| FMR LLC | 8,039,804 | $655.3M | 0.03% | +773,152+10.6% | Added |
| Vanguard Portfolio Management LLC | 6,351,355 | $517.7M | 0.02% | −794,781−11.1% | Reduced |
| Vanguard Capital Management LLC | 6,110,953 | $498.1M | 0.01% | +78,537+1.3% | Added |
| State Street Corp | 5,694,640 | $464.2M | 0.01% | −801,490−12.3% | Reduced |
| Norges Bank | 3,896,536 | $317.6M | 0.03% | +3,896,536 | New |
| Invesco Ltd. | 3,883,976 | $316.6M | 0.03% | +603,329+18.4% | Added |
| Geode Capital Management, LLC | 3,530,612 | $298.8M | 0.02% | −748,216−17.5% | Reduced |
| Fred Alger Management, LLC | 3,301,919 | $269.1M | 0.90% | −40,574−1.2% | Reduced |
Holders of 5% or more of ARWR
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Arrowhead Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 10.10%14.2M shares | −2.10 ppfrom 12.20% | Apr 23, 20254 filings | Jul 27, 2026 | SEC |
| Avoro Capital Advisors LLC | 13G/A | 9.64%13.8M shares | +1.34 ppfrom 8.30% | Nov 14, 20244 filings | Aug 14, 2026 | SEC |
| FMR LLC | 13G/A | 6.60%9.31M shares | +1.40 ppfrom 5.20% | May 6, 20262 filings | Nov 5, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 5.05%7.08M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
Politician trades
All politician trades in ARWR1 member of Congress reported 1 trade in Arrowhead Pharmaceuticals, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Feb 24, 2023 |  Daniel S. Goldman House · NY | Sell | $1K-$15K |
House · NY · Feb 24, 2023
Sell$1K-$15K